BIIB logo

BiogenNasdaqGS:BIIB Stock Report

Market Cap US$18.3b
Share Price
n/a
1Y-45.9%
7D-7.8%
Portfolio Value
​
View

Biogen Inc.

NasdaqGS:BIIB Stock Report

Market Cap: US$18.3b

Biogen (BIIB) Stock Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. More details

BIIB fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 68.6% below our estimate of its fair value

Earnings are forecast to grow 7.53% per year

Earnings grew by 26.8% over the past year

Trading at good value compared to peers and industry

Risk Analysis

Large one-off items impacting financial results


BIIB Community Fair Values

Create Narrative

See what 79 others think this stock is worth. Follow their fair value or set your own to get alerts.

BIIB logo
Biogen
AN
AnalystConsensusTarget
AnalystConsensusTarget
Consensus Narrative from 31 Analysts

LEQEMBI, SKYCLARYS And ZURZUVAE Will Spark Future Opportunities

Key Takeaways Expanding Alzheimer's treatments, including LEQEMBI, and SKYCLARYS' success in major markets could significantly drive short-term revenue growth. Strategic focus on rare disease treatments, a robust late-stage pipeline, and external collaborations bolster long-term revenue growth and market expansion.
View narrative
US$173.10
FV
29.1% undervalued intrinsic discount
-2.10%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
50users have followed this narrative
5 days ago author updated this narrative
BIIB logo
Biogen
AN
AnalystLowTarget
AnalystLowTarget
Consensus Narrative from 31 Analysts

Rising Biosimilar Competition Will Erode Legacy Revenues

Key Takeaways Escalating competition and regulatory pressures threaten margins and revenue growth, especially for legacy neurology products and premium-priced therapies. Heavy reliance on a limited neurology pipeline magnifies risks tied to clinical outcomes and increased challenges from larger pharmaceutical rivals.
View narrative
US$115.00
FV
6.7% overvalued intrinsic discount
-5.11%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
5 days ago author updated this narrative
BIIB logo
Biogen
AN
AnalystHighTarget
AnalystHighTarget
Consensus Narrative from 31 Analysts

Alzheimer’s Treatments And Gene Therapies Will Expand Care Access

Key Takeaways Expanding focus on neurodegenerative diseases, new treatment options, and personalized therapies positions Biogen for sustained revenue growth and improved profitability. Diversification into rare diseases and advanced biologics, supported by ongoing pipeline development, reduces risk and enhances quality and stability of future earnings.
View narrative
US$257.67
FV
52.4% undervalued intrinsic discount
-0.44%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
5 days ago author updated this narrative
View Biogen Community

Biogen Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Biogen
Historical stock prices
Current Share PriceUS$122.68
52 Week HighUS$236.48
52 Week LowUS$110.04
Beta0.14
1 Month Change-3.43%
3 Month Change3.19%
1 Year Change-45.87%
3 Year Change-40.90%
5 Year Change-57.13%
Change since IPO3,878.81%

Recent News & Updates

Biogen: Investors Are Missing The Bigger Picture

Jun 23

Recent updates

Biogen: Investors Are Missing The Bigger Picture

Jun 23

Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly

Jun 17
Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly

Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?

Apr 25

Biogen: Balancing Risks And Opportunities

Mar 27

We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative

Feb 19
We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative

Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma

Feb 15

Is Biogen (NASDAQ:BIIB) A Risky Investment?

Feb 10
Is Biogen (NASDAQ:BIIB) A Risky Investment?

Beaten Down Biogen Stock Looks Attractive At Current Levels

Dec 30

Market Cool On Biogen Inc.'s (NASDAQ:BIIB) Earnings

Dec 24
Market Cool On Biogen Inc.'s (NASDAQ:BIIB) Earnings

Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter

Oct 31

Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?

Oct 01
Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?

What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Sep 04
What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark

Aug 17

Biogen Stock: Cheapish, But With Few Growth Prospects

Jul 11

Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)

Apr 29

Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

Feb 14

Biotech And Pharma Diversification Pays Off

Jan 25

Shareholder Returns

BIIBUS BiotechsUS Market
7D-7.8%-0.4%0.9%
1Y-45.9%-11.9%14.8%

Return vs Industry: BIIB underperformed the US Biotechs industry which returned -11.9% over the past year.

Return vs Market: BIIB underperformed the US Market which returned 14.8% over the past year.

Price Volatility

Is BIIB's price volatile compared to industry and market?
BIIB volatility
BIIB Average Weekly Movement4.3%
Biotechs Industry Average Movement11.5%
Market Average Movement6.4%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: BIIB has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: BIIB's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19787,605Chris Viehbacherwww.biogen.com

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.

Biogen Inc. Fundamentals Summary

How do Biogen's earnings and revenue compare to its market cap?
BIIB fundamental statistics
Market capUS$18.31b
Earnings (TTM)US$1.48b
Revenue (TTM)US$9.82b
12.2x
P/E Ratio
1.8x
P/S Ratio

Is BIIB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIIB income statement (TTM)
RevenueUS$9.82b
Cost of RevenueUS$2.39b
Gross ProfitUS$7.43b
Other ExpensesUS$5.95b
EarningsUS$1.48b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Jul 31, 2025

Earnings per share (EPS)10.10
Gross Margin75.65%
Net Profit Margin15.07%
Debt/Equity Ratio37.1%

How did BIIB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/21 23:08
End of Day Share Price 2025/07/21 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biogen Inc. is covered by 68 analysts. 35 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Brian SkorneyBaird
Ishan MajumdarBaptista Research